ATE301457T1 - Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor - Google Patents

Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Info

Publication number
ATE301457T1
ATE301457T1 AT96918465T AT96918465T ATE301457T1 AT E301457 T1 ATE301457 T1 AT E301457T1 AT 96918465 T AT96918465 T AT 96918465T AT 96918465 T AT96918465 T AT 96918465T AT E301457 T1 ATE301457 T1 AT E301457T1
Authority
AT
Austria
Prior art keywords
inhibitor
cyclooxygenase
agent containing
lipoxygenase
lipoxygenase inhibitor
Prior art date
Application number
AT96918465T
Other languages
English (en)
Inventor
Peter C Isakson
Gary D Anderson
Susan A Gregory
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of ATE301457T1 publication Critical patent/ATE301457T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96918465T 1995-06-12 1996-06-11 Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor ATE301457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48947295A 1995-06-12 1995-06-12
PCT/US1996/010106 WO1996041626A1 (en) 1995-06-12 1996-06-11 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor

Publications (1)

Publication Number Publication Date
ATE301457T1 true ATE301457T1 (de) 2005-08-15

Family

ID=23944013

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918465T ATE301457T1 (de) 1995-06-12 1996-06-11 Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor

Country Status (9)

Country Link
US (1) US6136839A (de)
EP (1) EP0833622B8 (de)
JP (1) JPH11507670A (de)
AT (1) ATE301457T1 (de)
AU (1) AU6111796A (de)
CA (1) CA2224517A1 (de)
DE (1) DE69635048T2 (de)
ES (1) ES2247604T3 (de)
WO (1) WO1996041626A1 (de)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003392A1 (en) * 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DK0880363T3 (da) 1996-02-13 2003-01-20 Searle & Co Kombinationer der omfatter en cyclooxygenase-2 hæmmer samt en leukotrien A4 hydrolasehæmmer, som har immunsuppressive virkninger
DE69709069T2 (de) * 1996-02-13 2002-07-04 G.D. Searle & Co., Chicago Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
IL127487A (en) * 1996-07-11 2002-04-21 Warner Lambert Co Use of thiazolidinone derivatives for the preparation of drugs for the treatment of neurodegenerative diseases
CA2283399C (en) * 1997-03-14 2006-02-21 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
AU725697B2 (en) * 1997-04-03 2000-10-19 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
ID23687A (id) * 1997-04-18 2000-05-11 Searle & Co Metode penggunaan penghambat siklooksigenase-2 dalam pencegahan penyakit kardiovaskuler
ES2203985T3 (es) * 1997-09-05 2004-04-16 Glaxo Group Limited Derivados de 2,3-diaril-pirazolo(1,5)piridazina, su preparacion y su uso como inhibidores de la ciclooxigenasa 2(cox-2)`.
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
TW587079B (en) * 1998-09-25 2004-05-11 Almirall Prodesfarma Ag 2-phenylpyran-4-one derivatives
CN1263755C (zh) 1998-11-03 2006-07-12 葛兰素集团有限公司 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
DE10001166A1 (de) * 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
IN191512B (de) * 2000-01-21 2003-12-06 Panacea Biotech
US6800297B2 (en) 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
GB0016787D0 (en) 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
US6545019B2 (en) * 2000-07-13 2003-04-08 Bristol-Myers Squibb Company Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
WO2002017896A2 (en) * 2000-08-29 2002-03-07 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
WO2002048148A2 (en) * 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridine derivatives
ATE301653T1 (de) * 2000-12-15 2005-08-15 Glaxo Group Ltd Pyrazolopyridine
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
DE60201074T2 (de) * 2001-03-08 2005-09-15 Smithkline Beecham Corp. Pyrazolopyridinderivate
EP1372643A1 (de) 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridine, verfahren zu ihrer herstellung und verwendung als therapeutika
EP1372642A1 (de) * 2001-03-30 2004-01-02 SmithKline Beecham Corporation Verwendung von pyrazolopyridinen als therapeutika
US7141569B2 (en) 2001-04-10 2006-11-28 Smithkline Beecham Corporation Antiviral pyrazolopyridine compounds
BR0209129A (pt) 2001-04-18 2005-12-20 Euro Celtique Sa Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
DK1385514T5 (da) 2001-04-18 2009-03-09 Euro Celtique Sa Spiroinden- og spiroindanforbindelser
EP1997818A3 (de) 2001-04-18 2009-04-08 Euro-Celtique S.A. Chinolinonderivate und ihre Verwendung zur Schmerzbehandlung
PT1975164E (pt) 2001-04-18 2010-04-20 Euro Celtique Sa Compostos de octa-hidrobenzimidazolona utilizados como analgésicos
ES2242028T3 (es) 2001-04-27 2005-11-01 Smithkline Beecham Corporation Derivados de pirazolo(1,5-a)piridina.
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
DE10121252A1 (de) * 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
HUP0400266A2 (hu) * 2001-06-21 2004-08-30 Smithkline Beecham Corp. Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
ATE364043T1 (de) * 2001-09-07 2007-06-15 Smithkline Beecham Corp Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
JP3605105B2 (ja) * 2001-09-10 2004-12-22 キヤノン株式会社 電子放出素子、電子源、発光装置、画像形成装置および基板の各製造方法
WO2003031446A1 (en) 2001-10-05 2003-04-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
AU2002357740A1 (en) * 2001-12-11 2003-06-23 Smithkline Beecham Corporation Pyrazolo-pyridine derivatives as antiherpes agents
DK1472225T3 (da) 2002-02-01 2010-08-09 Euro Celtique Sa 2-Piperazinpyridiner, som er anvendelige til behandling af smerte
AR039391A1 (es) * 2002-04-08 2005-02-16 Glaxo Group Ltd Compuesto de ciclopenteno, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
EP1927858B1 (de) 2002-04-29 2013-01-09 Euro-Celtique S.A. Konformativ eingeschränkte Peptide zur Bindung des ORL-1-Rezeptors
JP2005528418A (ja) * 2002-05-07 2005-09-22 アルタナ　ファルマ　アクチエンゲゼルシャフト 気道疾患を治療するための新規組み合わせ
BR0310068A (pt) * 2002-05-17 2005-03-08 Merckle Gmbh Uso de um ou mais de um composto, combinação, e, composição farmacêutica
US20040021778A1 (en) * 2002-08-05 2004-02-05 Oldani Jerome L. Security system with remote access and control
US20060004040A1 (en) * 2002-08-26 2006-01-05 Jilly Evans Method for the prevention and/or treatment of atherosclerosis
JP2006504728A (ja) * 2002-10-03 2006-02-09 スミスクライン ビーチャム コーポレーション ピラソロピリジン誘導体系治療用化合物
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PT1572217E (pt) * 2002-12-12 2008-11-28 Nycomed Gmbh Medicamento combinado de r,r-formoterol e ciclesonida
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
KR20060005375A (ko) * 2003-04-18 2006-01-17 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 피라졸 유도체
ES2275218T3 (es) * 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
BR0318395A (pt) 2003-07-10 2006-08-01 Arturo Jimenez Bayardo método para preparar uma solução aquosa de meloxicam e a solução aquosa resultante
BRPI0412808A (pt) * 2003-07-24 2006-09-26 Euro Celtique Sa compostos de piperidina e composições farmacêuticas contendo os mesmos
EP2080757A1 (de) * 2003-07-24 2009-07-22 Euro-Celtique S.A. Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
PL1867644T3 (pl) 2003-07-24 2009-10-30 Euro Celtique Sa Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
SI1942106T1 (sl) 2003-08-01 2012-01-31 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
US8371292B2 (en) * 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
DE602004017481D1 (de) * 2003-09-22 2008-12-11 Euro Celtique Sa Zur behandlung von schmerzen geeignete therapeutische mittel
PT2017276E (pt) 2003-09-22 2011-04-05 Euro Celtique Sa Compostos de fenilcarboxamida úteis para o tratamento da dor
US20060079566A1 (en) 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323584D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
DE10351035A1 (de) * 2003-10-31 2005-05-25 Merckle Gmbh Chemisch Pharmazeutische Fabrik Pharmazeutische Licofelone-Formulierung
DE602004031356D1 (de) * 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
CN1902178A (zh) * 2003-12-30 2007-01-24 欧洲凯尔特公司 用于治疗疼痛的哌嗪
US20050187277A1 (en) * 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
AU2005235384B2 (en) * 2004-04-20 2010-09-09 Covis Pharma B.V. Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
GB0410121D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds
JP2008502609A (ja) * 2004-06-17 2008-01-31 オステオロジックス エイ／エス リウマチおよび関節性疾患の治療改善方法
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
MX2007006777A (es) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
NZ556163A (en) * 2005-01-10 2011-11-25 Univ California Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors
SG164378A1 (en) 2005-02-17 2010-09-29 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US8193208B2 (en) * 2005-09-09 2012-06-05 Purdue Pharma L.P. Fused and spirocycle compounds and the use thereof
EA013510B1 (ru) 2005-11-21 2010-06-30 Пэдью Фарма Л.П. Соединения 4-оксадиазолилпиперидина и их применение
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
AU2007211319B9 (en) 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
EP1987009A1 (de) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cycloharnstoffverbindung als calciumkanalblocker
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
TW200815353A (en) 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
PT2079485E (pt) 2006-11-01 2012-08-13 Purdue Pharma Lp Compostos fenilpropionamida e a sua utilização
KR101370434B1 (ko) 2007-01-16 2014-03-06 시오노기세이야쿠가부시키가이샤 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
EP2131841B1 (de) * 2007-01-30 2012-08-01 Avigen, Inc. Verfahren zur behandlung von akuten schmerzen
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
EP2604599A1 (de) 2007-04-27 2013-06-19 Purdue Pharma LP TRPV1-Antagonisten und ihre Verwendung
EP2479173A1 (de) 2007-04-27 2012-07-25 Purdue Pharma LP Zur Behandlung von Schmerzen geeignete therapeutische Mittel
WO2008137012A1 (en) * 2007-05-03 2008-11-13 Avigen, Inc. Use of a glial attenuator to prevent amplified pain responses caused by glial priming
WO2008150447A1 (en) 2007-05-31 2008-12-11 Euro-Celtique S.A. Amide compounds and the use thereof
US8095213B1 (en) 2007-05-31 2012-01-10 Purdue Pharma L.P. Transdermal patch
US8214031B1 (en) 2007-05-31 2012-07-03 Purdue Pharma L.P. Switch for transdermal patch
US7853320B1 (en) 2007-05-31 2010-12-14 Purdue Pharma L.P. Transdermal device having mechanical assist for porator-to-skin contact
ES2422603T3 (es) * 2007-05-31 2013-09-12 Shionogi & Co Compuestos oxiimino y el uso de estos
US8047399B1 (en) 2007-07-05 2011-11-01 Purdue Pharma L.P. Dispenser for transdermal devices
MX2010000465A (es) 2007-07-12 2010-08-30 Tragara Pharmaceuticals Inc Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
KR20140139125A (ko) 2007-08-31 2014-12-04 퍼듀 퍼머 엘피 치환-퀴녹살린-형 피페리딘 화합물 및 그의 용도
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9044510B2 (en) 2007-11-01 2015-06-02 Washington University Compositions and methods for treating pruritus
EP2620437A1 (de) 2007-11-30 2013-07-31 Purdue Pharma LP Benzomorphanverbindungen
CA2794054C (en) * 2008-01-08 2014-11-25 Purdue Pharma L.P. Proline analogs as ligands for cannabinoid receptors
WO2009151152A1 (en) 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
CN102143736A (zh) 2008-07-17 2011-08-03 梅里亚有限公司 增强聚原酸酯和它们的制剂的稳定性的方法
HRP20120841T4 (hr) 2008-07-21 2015-07-03 Purdue Pharma L.P. Premošteni piperidinski spojevi substituiranog kinoksalin-tipa i njihova uporaba
UA104004C2 (uk) 2008-07-30 2013-12-25 Пердью Фарма Л.П. Аналоги бупренорфіну
WO2010014257A2 (en) * 2008-08-01 2010-02-04 Purdue Pharma L.P. Tetrahydropyridinyl and dihydropyrrolyl compounds and the use thereof
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8895551B2 (en) 2009-04-02 2014-11-25 Shionogi & Co., Ltd. Acrylamide compounds and the use thereof
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
US20100273203A1 (en) * 2009-04-23 2010-10-28 Board Of Trustees Of The University Of Arkansas Methods and compositions for detecting metabolites
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US8410064B2 (en) * 2009-08-24 2013-04-02 The Board Of Trustees Of The University Of Arkansas Classical cannabinoid metabolites and methods of use thereof
US8883218B2 (en) 2010-03-26 2014-11-11 The Board Of Trustees Of The University Of Arkansas Anti-cancer nanoparticle compositions and methods of use
EP2582666B1 (de) 2010-06-16 2014-08-13 Purdue Pharma L.P. Arylsubstituierte indole und ihre verwendung als kalzium-kanal-blocker
US9279003B2 (en) 2010-07-07 2016-03-08 Purdue Pharma L.P. Analogs of sodium channel peptide toxin
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
EP2616441B1 (de) 2010-09-17 2019-08-07 Purdue Pharma L.P. Pyridinverbindungen und ihre verwendung
AU2011311238A1 (en) 2010-10-05 2013-04-04 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
US9079899B2 (en) 2010-11-01 2015-07-14 The Ohio State University Anti-staphylococcal celecoxib derivatives
JP2014500303A (ja) 2010-12-22 2014-01-09 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としての置換ピリジン
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
US9095598B2 (en) 2010-12-28 2015-08-04 The Board Of Trustees Of The University Of Arkansas Stilbenoid derivatives and their uses
EP2680846A4 (de) * 2011-03-01 2014-08-06 Npharmakon Llc Verwendung von n-(4-methoxyphenyl)-1-phenyl-1h-pyrazol-3-amin und verbindungen in zusammenhang damit
SMT201700325T1 (it) 2011-03-23 2017-09-07 Trevena Inc Ligandi del recettore degli oppioidi e metodi per l’uso e la produzione dei medesimi
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US8957024B2 (en) 2011-07-27 2015-02-17 Washington University Composition and methods for reducing opioid-induced pruritus
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
AU2012300567B2 (en) 2011-09-02 2016-03-10 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
AU2012324010A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013080036A1 (en) 2011-12-01 2013-06-06 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
EP2788358B1 (de) 2011-12-08 2018-08-29 Purdue Pharma LP Quaternisierte buprenorphinanaloga
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
TW201408645A (zh) 2012-05-11 2014-03-01 Purdue Pharma Lp 苯並嗎凡類似物及其用途
US9718865B2 (en) 2012-07-27 2017-08-01 Purdue Pharma L.P. Sodium channel blocking peptides and the use thereof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2931729B1 (de) 2012-12-07 2019-02-06 Purdue Pharma LP Buprenorphinanaloga als opiodrezeptormodulatoren
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
CA2900023A1 (en) 2013-01-31 2014-08-07 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
US10716784B2 (en) 2013-03-07 2020-07-21 Mindlab LLC Pain medicine combination and uses thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
CA2906145A1 (en) 2013-03-15 2014-09-18 Ptc Therapeutics, Inc. Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
ES2729642T3 (es) 2013-09-24 2019-11-05 Purdue Pharma Lp Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
EP3086790A4 (de) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituierte und 7-substituierte morphinanaloge und verwendungen davon
BR112017017619A2 (pt) 2015-02-19 2018-05-08 Purdue Pharma Lp métodos e composições para diminuir esvaziamento gástrico
WO2016133788A1 (en) 2015-02-20 2016-08-25 The Regents Of The University Of California Methods of inhibiting pain
CN119302953A (zh) 2015-12-14 2025-01-14 特维娜Spv2有限责任公司 治疗痛觉过敏的方法
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
CN110446533A (zh) 2016-09-13 2019-11-12 思想实验室有限责任公司 不宁腿综合征的药品组合与治疗
US20190083386A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
JP2021501210A (ja) 2017-10-30 2021-01-14 モントリオール ハート インスティテュート 血漿コレステロールの上昇を処置する方法
EP3713916A1 (de) 2017-11-20 2020-09-30 Kiakos, Konstantinos Aus 3,5-diarylidenyl-n-substituiertes-piperid-4-on abgeleitete inhibitoren der stat3-weg-aktivität und verwendungen davon
US11251635B2 (en) 2017-12-19 2022-02-15 Welch Allyn, Inc. Vital signs monitor with a removable and dischargable battery
KR20240160681A (ko) 2018-01-24 2024-11-11 퍼듀 퍼머 엘피 수면 장애 치료 및 예방
ES2962999T3 (es) 2021-07-30 2024-03-22 Cannamedical Pharma Gmbh Parche transmucoso que comprende un cannabinoide y/o un opiáceo
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4472420A (en) * 1983-08-18 1984-09-18 Methodist Hospital Of Indiana, Inc. Method for treatment of shock
US4760086A (en) * 1985-02-27 1988-07-26 Merck & Co., Inc. N-alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors
EP0178035B1 (de) * 1984-05-12 1990-01-03 FISONS plc Antiinflammatorische 1,N-Diarylpyrazol-3-amine, deren Zusammensetzungen und Verfahren zu deren Herstellung
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US4769461A (en) * 1986-09-16 1988-09-06 American Home Products Corporation Quinolinyl benzene hydroxamic acids as anti-inflammatory/antiallergic agents
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
AU611437B2 (en) * 1987-05-29 1991-06-13 Ortho Pharmaceutical Corporation Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-n-hydroxypropanamides and method for synthesizing the same
US5242940A (en) * 1987-05-29 1993-09-07 Ortho Pharmaceutical Corporation Pharmacologically active N-1 and C-5 heterocyclic pyrazoles and method for synthesizing the same
WO1988009675A1 (en) * 1987-06-05 1988-12-15 Medicis Corporation Inhibition of arachidonic acid metabolism
PL154186B1 (en) * 1987-07-15 1991-07-31 Wellcome Found Method for manufacturing arylic derivatives of the hydroxamic acid
US4870210A (en) * 1987-12-18 1989-09-26 American Home Products Corporation Aminoguanidine derivative as anti-inflammatory agents
US5112868A (en) * 1988-05-19 1992-05-12 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
JPH0288553A (ja) * 1988-07-14 1990-03-28 Wellcome Found Ltd:The 抗炎症性アリール誘導体
US5234950A (en) * 1988-12-23 1993-08-10 Imperial Chemical Industries Plc Tetrahydrofuran derivatives
GB8927287D0 (en) * 1988-12-23 1990-01-31 Ici Plc Cyclic ether derivatives
US5128352A (en) * 1989-01-10 1992-07-07 Pfizer Inc. Anti-inflammatory 1-heteroaryl-oxindole-3-carboxamides
US5066668A (en) * 1989-06-09 1991-11-19 Warner-Lambert Co. Triazole derivatives of fenamates as antiinflammatory agents
JPH06759B2 (ja) * 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
CA2072018A1 (en) * 1989-12-16 1991-06-17 Colin Bennion Pharmacologically active amide carboxylate derivatives
JPH0717589B2 (ja) * 1990-01-22 1995-03-01 ファイザー製薬株式会社 新規１，３―ジカルボニル化合物およびその組成物
JPH0729998B2 (ja) * 1990-01-22 1995-04-05 ファイザー製薬株式会社 新規ベンゾキノン化合物およびその組成物
US5017604A (en) * 1990-04-11 1991-05-21 Warner-Lambert Company Novel fenamic acid methyl hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5220059A (en) * 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
AU8205991A (en) * 1990-06-12 1992-01-07 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
AU647177B2 (en) * 1990-07-25 1994-03-17 Abbott Laboratories Acetylenic urea derivatives having lipoxygenase inhibitory activity
US5476873A (en) * 1990-07-25 1995-12-19 Abbott Laboratories Acetylene derivatives having lipoxygenase inhibitory activity
JPH04134077A (ja) * 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
IE913655A1 (en) * 1990-11-06 1992-05-22 Zeneca Ltd Synergistic agents
DE4037426A1 (de) * 1990-11-24 1992-05-27 Kali Chemie Pharma Gmbh Piperidinoalkylbenzoxazin- und -thiazin-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ZA919797B (en) * 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
CA2365269A1 (en) * 1991-01-31 1992-08-20 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
CA2081781A1 (en) * 1991-03-05 1992-09-06 Shuichi Takeda Allyl alcohol derivative
EP0633254A1 (de) * 1991-05-01 1995-01-11 Taiho Pharmaceutical Co., Ltd. Neue isoxazolderivate und ihre salze
FR2677355B1 (fr) * 1991-06-06 1993-08-20 Bellon Labor Sa Roger Nouveaux derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
JPH07502263A (ja) * 1991-09-13 1995-03-09 ボロン．バイオロジカルス．インコーポレイテッド 有機ホウ素化合物を利用して、動物の骨粗鬆症及びその他の病気を治療する方法
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5354865A (en) * 1992-09-10 1994-10-11 Abbott Laboratories Phenylmethyl derivatives having lipoxygenase inhibitory activity
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (de) * 1993-01-15 1997-11-19 G.D. Searle & Co. 3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en) * 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
GB9308652D0 (en) * 1993-04-27 1993-06-09 Wellcome Found Anti-inflammatory compounds
IL109430A0 (en) * 1993-04-27 1994-07-31 Wellcome Found Hydroxamic acid derivatives, their preparation and pharmaceutical compositions containing them
CA2161789A1 (en) * 1993-05-13 1994-11-24 Jacques Yves Gauthier 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en) * 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9312204D0 (en) * 1993-06-14 1993-07-28 Zeneca Ltd Therapeutic composition
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5298521A (en) * 1993-08-30 1994-03-29 Ortho Pharmaceutical Corporation 1,5-diphenyl-3-pyrazolylalkyl-N-hydroxydithiocaramates, compositions and use
US5344991A (en) * 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5393790A (en) * 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs

Also Published As

Publication number Publication date
EP0833622A1 (de) 1998-04-08
DE69635048D1 (de) 2005-09-15
EP0833622B8 (de) 2005-10-12
DE69635048T2 (de) 2006-02-16
CA2224517A1 (en) 1996-12-27
AU6111796A (en) 1997-01-09
WO1996041626A1 (en) 1996-12-27
US6136839A (en) 2000-10-24
ES2247604T3 (es) 2006-03-01
JPH11507670A (ja) 1999-07-06
EP0833622B1 (de) 2005-08-10

Similar Documents

Publication Publication Date Title
DE69635048D1 (de) Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
ATE322893T1 (de) Mittel, die einen cyclooxygenase-2 inhibitor und einen leukotrien a 4 hydrolaseinhibitor enthalten
IL138028A0 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
TR200102499T2 (tr) Neoplazi tedavisinde bir kombinasyon terapisi olarak bir siklooksijenaz-2 inhibitörü ve bir veya daha fazla antineoplastik ajan kullanma yöntemi
TR199801930T2 (xx) 6-Fenilpiridil-2-amin t�revleri.
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
DK0827537T3 (da) Chromatin-regulator-gener
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
NL1003300A1 (nl) Implanteerbare therapeutische inrichting.
EP0813544A4 (de)
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
ZA968785B (en) Snatch block pins.
DE69427485D1 (de) Verbindungen, zubereitungen und behandlung von allergien und entzündungen
WO1998018440A3 (fr) Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles
MY129782A (en) Novel medical use
AU1278600A (en) Novel therapeutic application of nicergoline
ATE28188T1 (de) Antikonvulsive mittel.
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
EP1083914A4 (de) Behandlung der arthritis und anderer ähnlicher störungen
ATE213644T1 (de) Kombinationstherapie für die behandlung von arthritis erkrankungen
NO963988L (no) Hypokolesterolemiske-, antiatherosklerotiske-, og hypotriglyceridemiske mercaptoacetylamidderivater
PT1133297E (pt) Nova aplicacao terapeutica da 1,6-dimetil-8beta-hidroximetil-10alfa-metoxiergolina
GEU1998400Y (en) Ointment “Topokril” for Treating of Dermatitis
FR2708283B1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties